MoneyWorks4Me

Sanjivani Paranteral - Quaterly Results

27 May 2025 Evaluate
The sales moved up 41.33% to Rs. 181.81 millions for the March 2025 quarter as compared to Rs. 128.64 millions during the year-ago period.Profit after tax for the quarter ended March 2025 reported a huge growth of 74.32% to Rs. 21.93  millions from Rs. 12.58 millions.Operating profit for the quarter ended March 2025 rose to 30.47 millions as compared to 22.11 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 181.81 128.64 41.33 700.99 544.10 28.83 700.99 544.10 28.83
Other Income 4.27 0.52 721.15 12.14 5.17 134.82 12.14 5.17 134.82
PBIDT 30.47 22.11 37.81 115.73 87.58 32.14 115.73 87.58 32.14
Interest 2.02 0.88 129.55 5.93 2.54 133.46 5.93 2.54 133.46
PBDT 28.45 21.23 34.01 109.80 85.04 29.12 109.80 85.04 29.12
Depreciation 1.84 2.38 -22.69 6.21 9.33 -33.44 6.21 9.33 -33.44
PBT 26.61 18.85 41.17 103.59 75.71 36.82 103.59 75.71 36.82
TAX 4.68 6.27 -25.36 22.58 14.07 60.48 22.58 14.07 60.48
Deferred Tax 4.13 0.48 760.42 4.13 0.48 760.42 4.13 0.48 760.42
PAT 21.93 12.58 74.32 81.01 61.64 31.42 81.01 61.64 31.42
Equity 118.82 116.84 1.69 118.82 116.84 1.69 118.82 116.84 1.69
PBIDTM(%) 16.76 17.19 -2.49 16.51 16.10 2.57 16.51 16.10 2.57
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..